Pulse Biosciences, Inc.’s Nano-Pulse Stimulation Technology Produces Favorable Results for Warts and All
NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
Three studies show positive results for Pulse Biosciences, Inc.’s investigational use of Nano-Pulse Stimulation non-thermal energy in nodular basal cell carcinoma (BCC), sebaceous hyperplasia (SH) lesions and cutaneous non-genital warts.
In addition, pre-clinical observations of the effect of NPS energy on murine melanoma and liver tumors in situ look promising, according to findings were presented at the virtual annual conference of the American Society for Laser Medicine and Surgery (ASLMS).
“The robust body of clinical evidence demonstrated in the studies…outline the broad functional benefits of Nano-Pulse Stimulation technology in aesthetic and therapeutic dermatology. These results help to advance our goal of bringing a potentially paradigm-changing procedure to patients wishing to improve the health and appearance of their skin,” says Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences, in a news release.
More on the Wart Study
“Our interim findings of 87 treated warts on 27 patients showed improved efficacy with respect to high clearance ratings and no recurrence at 60 days after the last NPS treatment. Interestingly, NPS technology was particularly effective in clearing warts on the knees, hands, and legs,” says E. Victor Ross, MD, Director of the Laser and Cosmetic Dermatology Center at Scripps Clinic in San Diego, Calif. of the wart study. “Furthermore, no plume was reported in a sub-cohort of patient treatments, as confirmed by a particulate counter. This could be a major advantage over thermal modalities that produce a plume of vapor or smoke that can contain contaminated debris particles since protecting the health and safety of our patients is always our top concern."
If cleared, the CellFX System, a multi-application platform for delivering NPS technology, will be the first commercial product to harness the distinctive advantages of the Company’s proprietary NPS technology. NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications.